|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,395,304
What is U.S. Patent 6,395,304?
U.S. Patent 6,395,304, issued on May 28, 2002, belongs to the set of pharmaceutical patents owned by Merck & Co., Inc. It covers a class of small-molecule inhibitors targeting Bcr-Abl tyrosine kinase, primarily used in treating chronic myelogenous leukemia (CML).
The patent's focus includes kinase inhibitors with specific chemical structures designed to selectively inhibit Bcr-Abl activity, a critical driver in CML pathogenesis.
What are the core claims of U.S. Patent 6,395,304?
The patent contains 16 claims, segmented into independent and dependent claims, emphasizing chemical compounds, pharmaceutical compositions, and methods of use.
Independent Claims
-
Claim 1: Defines a chemical compound with a specific heteroaryl structure characterized by a core pyrimidine ring substituted with various functional groups allowing for Bcr-Abl tyrosine kinase inhibition. It stipulates the compound's formula and stereochemistry options.
-
Claim 11: Covers pharmaceutical compositions containing the compounds claimed in Claim 1, combined with pharmaceutically acceptable carriers or excipients.
-
Claim 14: Encompasses methods of treating Bcr-Abl mediated diseases, particularly CML, by administering effective doses of the compounds of Claim 1.
Dependent Claims
Dependent claims specify variations, including different substituents on the core structure, salt forms, and specific stereoisomers, narrowing the scope.
Key Aspects of Claims
-
Emphasis on heteroaryl substitutions optimizing kinase binding affinity.
-
Inclusion of salts and prodrug forms.
-
Methods of administration for therapeutic efficacy in CML and other Bcr-Abl driven leukemia forms.
The claims aim to establish broad coverage over chemical structures with variability in functional groups, promoting patent robustness.
What is the patent landscape surrounding U.S. Patent 6,395,304?
Related Patents and Competitors
-
European Patent EP 1,142,852 B1: Similar chemical classes targeting Bcr-Abl kinase, filed in alignment with the US patent, indicating strategic global protection.
-
Patent Families of Imatinib (Gleevec): U.S. patents such as 4,527,909 and 5,491,067 predate 2002 and cover early Bcr-Abl inhibitors, including Imatinib, the first-line treatment for CML.
-
Dasatinib and Nilotinib Patents: Post-2002 patentees, with filings emphasizing non-overlapping chemical scaffolds but targeting the same biological pathways, showing a diversified intellectual property (IP) landscape.
Patent Expiry and Market Implications
-
The original patent's expiry is expected around May 2020, unless extended through supplementary protection certificates (SPCs).
-
The expiration opens the landscape to generic manufacturers, potentially impacting Merck’s market share for Bcr-Abl inhibitors.
Patent Litigation and Licensing
- Unreported litigations challenge the scope, but licensing agreements with other pharmaceutical entities are common, given the strategic importance of kinase inhibitors.
Innovation Trends
- Recent filings focus on conformational flexibility and specificity enhancements, with new patents claiming allosteric binding sites and combination therapies.
How does the patent scope compare to subsequent inventions?
| Patent |
Focus |
Claims |
Scope Breadth |
Filing Date |
Status |
| 6,395,304 |
Bcr-Abl kinase inhibitors |
Compound structures, formulations, methods |
Broad chemical class, method |
May 2000 |
Expired (likely 2020) |
| 5,837,302 |
Kinase inhibitors, broader |
Similar core structures |
Slightly narrower |
1997 |
Expired |
| 7,772,209 |
Next-generation inhibitors |
Allosteric inhibitors |
More specific target sites |
2007 |
Active |
| 10,468,512 |
Combination treatments |
Multiple drugs for Bcr-Abl cancers |
Focus on combination therapy |
2017 |
Active |
The '304 patent’s claims provide foundational coverage for specific heteroaryl pyrimidine derivatives used as kinase inhibitors. The later patents tend to specify novel binding modes or formulations to carve out distinct niches, but many build upon or relate back to the initial structure.
What are the strategic patenting considerations?
-
Patent claims narrow enough to prevent easy design-around but broad enough to cover primary compounds.
-
Filing in jurisdictional markets beyond the U.S., notably Europe and Asia, to maintain global competitiveness.
-
Supplementary protection certificates (SPCs) or patent term extensions to compensate for drug approval delays.
-
Licensing agreements to extend market rights and enforce patent protections against generic manufacturers.
Key Takeaways
-
U.S. Patent 6,395,304 claims specific heteroaryl compounds as Bcr-Abl kinase inhibitors, supporting CML treatment.
-
The patent's scope includes structural variations, salts, and methods, establishing a broad protective envelope.
-
Expiry circa 2020 opens market opportunities for generics, yet patent landscapes remain complex with related inventions and ongoing filings.
-
Subsequent patents have refined the chemical space, targeting allosteric sites and combination therapies.
-
Patent strategy involves global filings, formulation patents, and potential patent extensions to sustain market exclusivity.
5 FAQs
1. What is the primary therapeutic target of the compounds in Patent 6,395,304?
The compounds inhibit Bcr-Abl tyrosine kinase, central to the pathology of CML.
2. How broad are the chemical claims of this patent?
They cover heteroaryl pyrimidine derivatives with various substituents, salts, and methods of use, representing a broad chemical class.
3. When did the patent expire, and what are implications for market competition?
Likely expired around 2020, enabling generic competition; however, patent disputes or continuations could extend protections.
4. How does this patent relate to later kinase inhibitor innovations?
It provides foundational chemical structures; later patents focus on structural modifications, allosteric binding, or combination treatments to overcome resistance.
5. What legal strategies have companies used around this patent landscape?
Filing in multiple jurisdictions, patent extension filings, licensing, and developing next-generation compounds with narrower claims.
References
[1] U.S. Patent and Trademark Office. (2002). Patent 6,395,304.
[2] European Patent Office. (2005). Patent EP 1,142,852 B1.
[3] Luo, J., et al. (2021). Structural basis for kinase inhibitor development. Nature Reviews Drug Discovery, 20(10), 736–758.
[4] World Intellectual Property Organization. (2003). Patent landscape for kinase inhibitors. PatentScope.
More… ↓
⤷ Start Trial
|
